Use

Ki‑67 (MIB‑1) is a proliferation marker used to identify patients with hormone receptor‑positive (HR+), HER2‑negative early breast cancer at high risk of recurrence who may benefit from adjuvant therapy with abemaciclib (Verzenio®) in combination with endocrine therapy, when Ki‑67 score is ≥20%, as determined by an FDA‑approved companion diagnostic test.

Not provided.